Equine endotoxaemia–a state-of-the-art review of therapy.

The research article focuses on the understanding of Equine endotoxaemia, a leading cause of death in horses, and explores potential therapeutic agents along with highlighting the importance of supportive care as a critical treatment approach.

Understanding Equine Endotoxaemia

• Endotoxaemia is a serious condition common in horses, characterized by the presence of endotoxins in the blood. The pathophysiology of the condition is complex and involves various ways in which endotoxins can be absorbed into the systemic circulation. Most often, the body’s defense mechanisms are either disrupted, bypassed, or overwhelmed, leading to systemic endotoxin absorption.
• Following the systemic absorption of endotoxins, widespread effects are observed in the body, most predominantly in the cardiovascular system. Fever, arterial hypoxaemia (low oxygen levels in the blood), and signs of abdominal pain are also commonly seen.

Importance of Supportive Care in Treatment

• As our understanding of the disease improves, new therapeutic agents are becoming available. While these newer agents offer some advantages, the research underscores that supportive care remains the core treatment for endotoxaemia.
• Supportive care involves aggressive fluid therapy which includes crystalloid, colloid, and hypertonic therapies. The administration of non-steroidal anti-inflammatory drugs and antimicrobials, where appropriate, also forms a crucial part of the treatment.
• The specific principles of supportive care and its vital role in treating endotoxaemia are discussed in detail in the research.

Other Therapies and Future Treatments

• The research also provides a comprehensive review of other therapies commonly used in treating equine endotoxaemia. These include hyperimmune plasma, polymyxin B, pentoxifylline, dimethyl sulfoxide, and heparin.
• Future potential treatments are also mentioned in the research – newer agents like anti-tumor necrosis factor antibodies, detergent, activated protein C, and insulin. Even though they have not yet gained widespread acceptance, they could play a vital role in endotoxaemia treatment in the future.